Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tapinarof for Cutaneous Lupus Erythematosus
NCT06661213Phase 1Enrolling by invitation
- Sponsor
- Northwestern University
- Start
- Apr 2025
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tapinarof in cutaneous lupus erythematosus (CLE), sponsored by Northwestern University. Primary endpoints: Cutaneous Lupus Activity Investigator Global Assessment - Revised score at 16 weeks and CLE Disease Area and Severity Index - Activity score at 16 weeks. Started Apr 2025; status: enrolling by invitation.
02
Drugs
tapinarof
03
Conditions
cutaneous lupus erythematosus (CLE)
Beyond the preview
Go deeper on NCT06661213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06661213.